CV Therapeutics is a biopharmaceutical company engaged in the discoveryand development of new small molecule drugs to treat cardiovascular disease, the leading cause of death in the United States. The company has several research and preclinical development programs designed to bring additional drug candidates into human clinical testing. The company is conducting clinical trials for two of our drug candidates, including ranolazine, which is in its second Phase III trial.